<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02269943</url>
  </required_header>
  <id_info>
    <org_study_id>CC-486-NPC-001</org_study_id>
    <secondary_id>2014-001745-25</secondary_id>
    <nct_id>NCT02269943</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Oral Azacitidine in Previously Treated Subjects With Locally Advanced or Metastatic Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Phase 2, Multicenter, International, Single Arm Study to Assess the Safety and Efficacy of Single Agent Cc-486 (Oral Azacitidine) in Previously Treated Subjects With Locally Advanced or Metastatic Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of CC-486 in previously
      treated subjects with locally advanced or metastatic nasopharyngeal carcinoma having failed
      one to two previous regimens, including platinum-based chemotherapy. Approximately 51-55
      subjects will be enrolled according to a Simon two-stage design; if the predefined activity
      is met (&gt;4 responses [complete response; partial response {CR/PR}] out of the first 17
      evaluable subjects based on independent radiological assessment), then the study will
      continue to enroll an additional 34 subjects. If &lt; or = 4 responses out of 17 are observed,
      then the study enrollment will be stopped.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 13, 2015</start_date>
  <completion_date type="Actual">April 20, 2017</completion_date>
  <primary_completion_date type="Actual">April 20, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>The combined incidence of complete response (CR) and partial response (PR), confirmed no less than 4 weeks after the criteria for response are first met, based on independent radiology assessment using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, or death whichever is earlier.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>Time from start of the study treatment to progression based on independent radiology assessment using RECIST Version 1.1, or death, whichever is earlier.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Time from first treatment to death by any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC</measure>
    <time_frame>Days 1 and 14</time_frame>
    <description>Area under the plasma concentration time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Cmax</measure>
    <time_frame>Days 1 and 14</time_frame>
    <description>Maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - t1/2</measure>
    <time_frame>Days 1 and 14</time_frame>
    <description>Terminal half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Tmax</measure>
    <time_frame>Days 1 and 14</time_frame>
    <description>Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - CL/F</measure>
    <time_frame>Days 1 and 14</time_frame>
    <description>Apparent clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Vz/F</measure>
    <time_frame>Days 1 and 14</time_frame>
    <description>Volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>Up to 2 Yrs</time_frame>
    <description>Stable Disease from the date of the first treatment or Complete Response or Partial Response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Nasopharyngeal Neoplasms</condition>
  <arm_group>
    <arm_group_label>CC-486</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-486 will be administered orally every day on Days 1-14 of a 21 day cycle at a dose of 300mg. The first 6 evaluable for safety subjects of Asian-Pacific ethnicity, a starting dose of 200 mg will be tested. If there are no safety concerns, the 300 mg dose will be administered to all subsequent subjects of Asian-Pacific ethnicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-486</intervention_name>
    <arm_group_label>CC-486</arm_group_label>
    <other_name>oral azacitidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age = or &gt; 18 years Histological or cytological diagnosis of undifferentiated or
             poorly differentiated nasopharyngeal carcinoma that is locally advanced or metastatic.

          -  Disease progression either clinically or radiographically after 1-2 previous regimens.

          -  Patient has received a platinum containing regimen. Eastern Cooperative Oncology Group
             (ECOG) performance status 0-2. Radiographically-documented measureable disease.

          -  Adequate organ and bone marrow functions.

          -  Willingness to follow pregnancy precautions.

        Exclusion Criteria:

          -  History of, or current brain metastasis. Any other malignancy within 5 years prior to
             randomization with the exception of adequately treated in situ carcinoma of the
             cervix, uteri, or non-melanomatous skin cancer (all treatment of which should have
             been completed 6 months prior to enrollment), in situ squamous cell carcinoma of the
             breast, or incidental prostate cancer.

          -  Previous treatment with azacitidine (any formulation), decitabine, any other
             hypomethylating agent.

          -  History of Gastrointestinal disorder or defect. Impaired ability to swallow oral
             medication. Persistent diarrhea or malabsorption.

          -  Active cardiac disease and HIV infection

          -  Active Bleeding; Pathological condition that carries a high risk of bleeding; risk of
             pseudoaneurysm of the internal carotid artery and carotid blowout syndrome.

          -  Major surgery within 14 days prior to starting Investigational Product or has not
             recovered from major side effects.

          -  Another investigational therapy within 28 days or 5 half lives of
             randomization/enrollment, whichever is shorter.

          -  Patient has not recovered from the acute toxic effects of prior anticancer therapy,
             radiation, or major surgery/significant trauma.

          -  Radiotherapy &lt; or = 4 weeks or limited field radiation for palliation &lt; or = 2 weeks
             prior to starting with the investigational product.

          -  Pregnancy/Breast feeding

          -  Any condition that places the patient at unacceptable risk if he/she were to
             participate in the study or that confounds the ability to interpret data from the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abderahim (Rahim) Fandi, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Comprehensive Cancer Care Clinic</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Hospitalier Franco-Britannique</name>
      <address>
        <city>Levallois-Perret</city>
        <zip>92300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Heraklion</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thermi Clinic</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Dei Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Singapore</city>
        <zip>169-610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore Oncology Consultants</name>
      <address>
        <city>Singapore</city>
        <zip>258500</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Singapore International Medical Centre</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Catalan de Oncologia-Hospital Duran</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation, Kaohsiung Memorial Hospital</name>
      <address>
        <city>Niao-Sung Hsiang Kaohsiung County</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Abderrahman Mami de Pneumo-Phtisiologie de l'Ariana</name>
      <address>
        <city>Ariana</city>
        <zip>2080</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Salah Azaiez</name>
      <address>
        <city>Bab Saadoun</city>
        <zip>1006</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Habib Bourguiba</name>
      <address>
        <city>Sfax</city>
        <zip>3029</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Tunisia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
    <country>Romania</country>
  </removed_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2014</study_first_submitted>
  <study_first_submitted_qc>October 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic nasopharyngeal carcinoma</keyword>
  <keyword>oral azacitidine</keyword>
  <keyword>oral AZA</keyword>
  <keyword>CC-486</keyword>
  <keyword>metastatic</keyword>
  <keyword>recurrent</keyword>
  <keyword>nasopharyngeal carcinoma</keyword>
  <keyword>nasal</keyword>
  <keyword>solid tumors</keyword>
  <keyword>locally advanced</keyword>
  <keyword>rare head and neck cancer</keyword>
  <keyword>nasopharynx</keyword>
  <keyword>single chemotherapy agent</keyword>
  <keyword>Epstein-Barr Virus (EBV) + nasopharyngeal carcinoma</keyword>
  <keyword>EBV-DN</keyword>
  <keyword>Celgene</keyword>
  <keyword>Sponsor-study</keyword>
  <keyword>oral chemotherapy</keyword>
  <keyword>phase 2</keyword>
  <keyword>oral Vidaza</keyword>
  <keyword>EBV promoter methylation</keyword>
  <keyword>hypomethylation</keyword>
  <keyword>tumor infiltrating lymphocytes (TILs)</keyword>
  <keyword>EBV gene expression</keyword>
  <keyword>neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 16, 2018</submitted>
    <returned>May 15, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

